Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation

British Journal of Pharmacology

Volumn 156, Issue 2, 2009, Pages 284-296

  Liu, Jun Yan ^a   Tsai, Hsing Ju ^a   Hwang, Sung Hee ^a   Jones, Paul D ^a   Morisseau, Christophe ^a   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bioavailability; Efficacy; LC MS MS; LPS; Murine; Oxylipin mediators; Pharmacokinetics; SEH inhibitor

Indexed keywords

12 (3 ADAMANTAN 1 YLUREIDO)DODECANOIC ACID; 4 [4 (3 ADAMANTAN 1 YLUREIDO)CYCLOHEXYLOXY]BENZOIC ACID; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; EPOXIDE HYDROLASE; EPOXIDE HYDROLASE INHIBITOR; LIPOPOLYSACCHARIDE; UNCLASSIFIED DRUG; 4 (4 (3 ADAMANTAN 1 YLUREIDO)CYCLOHEXYLOXY)BENZOIC ACID; 4-(4-(3-ADAMANTAN-1-YLUREIDO)CYCLOHEXYLOXY)BENZOIC ACID; BENZOIC ACID DERIVATIVE; DRUG DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; HUMAN CELL; IC 50; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; BIOAVAILABILITY; BIOLOGICAL MODEL; C57BL MOUSE; DISEASE MODEL; DRUG ANTAGONISM; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; SOLUBILITY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BENZOIC ACIDS; BIOLOGICAL AVAILABILITY; DISEASE MODELS, ANIMAL; EPOXIDE HYDROLASES; INFLAMMATION; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; SOLUBILITY; UREA;

EID: 67650228182     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2008.00009.x     Document Type: Article

References (48)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edn. Br J Pharmacol 153 : S1 S209.
2. Campbell WB (2000). New role for epoxyeicosatrienoic acids as anti-inflammatory mediators. Trends Pharmacol Sci 21 : 125 127.
3. Carroll MA, Schwartzman M, Capdevila J, Falck JR, McGiff JC (1987a). Vasoactivity of arachidonic acid epoxides. Eur J Pharmacol 138 : 281 283.
4. Carroll MA, Schwartzman ML, Capdevila J, Falck JR, Carrara MC, Mcgiff JC (1987b). Vascular activity of 5,6 epoxyeicosatrienoic acid. Clin Res 35 : A266 A266.
5. Davis BB, Morisseau C, Newman JW, Pedersen TL, Hammock BD, Weiss RH (2006). Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition. J Pharmacol Exp Ther 316 : 815 821.
6. Doggrell SA (2005). Cytochrome P-450: a new target in the heart and coronary circulation. Drugs Future 30 : 261 269.
7. Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD, Imig JD (2005). An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 46 : 842 848.
8. Elbekai RH, El-Kadi AOS (2006). Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol Ther 112 : 564 587.
9. Fleming I, Busse R (2006). Endothelium-derived epoxyeicosatrienoic acids and vascular function. Hypertension 47 : 629 633.
10. Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock B (2007). Orally bioavailable potent soluble Epoxide Hydrolase (sEH) inhibitors. J Med Chem 50 : 3825 3840.
11. Imig JD (2005). Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 289 : F496 F503.
12. Imig JD (2006). Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. Cardiovasc Drug Rev 24 : 169 188.
13. Imig JD, Falck JR, Navar LG (1995). 11,12-Epoxyeicosatrienoic acid (11,12-Eet) is a potent vasodilator of the renal microvasculature. J Am Soc Nephrol 6 : 679 679.
14. Imig JD, Zhao XY, Capdevila JH, Morisseau C, Hammock BD (2002). Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39 : 690 694.
15. Imig JD, Zhao XY, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW et al. (2005). An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46 : 975 981.
16. Inceoglu B, Schmelzer K, Jinks S, Waite T, Hammock B (2006). Soluble epoxide hydrolase inhibitors and/or epoxyeicosatrianoic acids attenuate hyperalgesia and allodynia in a rat model. FASEB J 20 : A687 A687.
17. Inceoglu B, Schmelzer KR, Morisseau C, Jinks SL, Hammock BD (2007). Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat 82 : 42 49.
18. Jin LM, Foss CE, Zhao XY, Mills TM, Wang MH, McCluskey LP et al. (2006). Cytochrome P450 epoxygenases provide a novel mechanism for penile erection. FASEB J 20 : 539 541.
19. Jones PD, Wolf NM, Morisseau C, Whetstone P, Hock B, Hammock BD (2005). Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies. Anal Biochem 343 : 66 75.
20. Jones PD, Tsai HJ, Do ZN, Morisseau C, Hammock BD (2006). Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett 16 : 5212 5216. (Pubitemid 44247687)
21. Kim IH, Morisseau C, Watanabe T, Hammock BD (2004). Design, synthesis, and biological activity of 1,3-Disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J Med Chem 47 : 2110 2122.
22. Kim IH, Heirtzler FR, Morisseau C, Nishi K, Tsai HJ, Hammock BD (2005). Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem 48 : 3621 3629.
23. Kim IH, Nishi K, Tsai HJ, Bradford T, Koda Y, Watanabe T et al. (2007). Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase. Bioorganic. Med Chem 15 : 312 323.
24. Luria A, Weldon SM, Kabcenell AK, Ingraham RH, Matera D, Jiang HP et al. (2007). Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J Biol Chem 282 : 2891 2898.
25. Morisseau C, Hammock BD (2007). Measurement of soluble epoxide hydrolase (sEH) activity. Curr Protoc Toxicol 33 : 1 18.
26. Morisseau C, Goodrow MH, Dowdy D, Zheng J, Greene JF, Sanborn JR et al. (1999). Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc Natl Acad Sci USA 96 : 8849 8854.
27. Morisseau C, Goodrow MH, Newman JW, Wheelock CE, Dowdy DL, Hammock BD (2002). Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol 63 : 1599 1608.
28. Morisseau C, Newman JW, Tsai HJ, Baecker PA, Hammock BD (2006a). Peptidyl-urea based inhibitors of soluble epoxide hydrolases. Bioorg Med Chem Lett 16 : 5439 5444.
29. Morisseau C, Schmelzer K, Pedersen T, Eiserich J, Pinkerton K, Imig J et al. (2006b). Physiological roles of soluble epoxide hydrolase and therapeutic prospects of its inhibition. FASEB J 20 : A669 A669.
30. Newman JW, Watanabe T, Hammock BD (2002). The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/MS. J Lipid Res 43 : 1563 1578.
31. Newman JW, Morisseau C, Hammock BD (2005). Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog Lipid Res 44 : 1 51.
32. Ng VY, Morisseau C, Falck JR, Hammock BD, Kroetz DL (2006). Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1. Arterioscler Thromb Vasc Biol 26 : 2462 2468.
33. Node K, Huo YQ, Ruan XL, Yang BC, Spiecker M, Ley K et al. (1999). Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285 : 1276 1279.
34. Olearczyk JJ, Kim IH, Hammock BD, Imig JD (2005). Inhibition of the soluble epoxide hydrolase decreases the expression of pro-inflammatory genes in hypertensive Goto-Kakizaki rats. Hypertension 46 : 856 856.
35. Olearczyk JJ, Field MB, Kim IH, Morisseau C, Hammock BD, Imig JD (2006a). Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels. J Pharmacol Exp Ther 318 : 1307 1314.
36. Olearczyk JJ, Field MB, Kim IH, Morisseau C, Hammock BD, Imig JD (2006b). Urea-based soluble epoxide hydrolase inhibitors dilate mesenteric resistance vessels. FASEB J 20 : A669 A669.
37. Pomposiello SI, Quilley J, Carroll MA, Falck JR, McGiff JC (2003). 5,6-epoxyeicosatrienoic acid mediates the enhanced renal vasodilation to arachidonic acid in the SHR. Hypertension 42 : 548 554.
38. Sarkis A, Roman RJ (2004). Role of cytochrome P450 metabolites of arachidonic acid in hypertension. Curr Drug Metab 5 : 245 256.
39. Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, Hammock BD (2005). Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA 102 : 9772 9777.
40. Schmelzer KR, Inceoglu B, Kubala L, Kim IH, Jinks SL, Eiserich JP et al. (2006). Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 103 : 13646 13651.
41. Seubert JM, Sinal CJ, Graves J, DeGraff LM, Bradbury JA, Lee CR et al. (2006). Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res 99 : 442 450.
42. Seubert JM, Zeldin DC, Nithipatikom K, Gross GJ (2007). Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat 82 : 50 59.
43. Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ, Hammock BD (2005). Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci USA 102 : 2186 2191.
44. Spector AA, Fang X, Snyder GD, Weintraub NL (2004). Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 43 : 55 90.
45. Watanabe T, Schulz D, Morisseau C, Hammock BD (2006). High-throughput pharmacokinetic method: Cassette dosing in mice associated with minuscule serial bleedings and LC/MS/MS analysis. Anal Chim Acta 559 : 37 44.
46. Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai HJ et al. (2006). Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 103 : 18733 18738.
47. Zhang WR, Koerner IP, Noppens R, Grafe M, Tsai HJ, Morisseau C et al. (2007). Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cerebral Blood Flow Metab 27 : 1931 1940.
48. Zhao XY, Inscho EW, Morisseau C, Hammock BD, Imig JD (2002). Soluble epoxide hydrolase regulates renal microvascular angiotensin II reactivity in hypertension. FASEB J 16 : A418 A418.